Contact Us at Sunridge Medical

Call Us Today! 1.800.923-7878

Contact Us
Call Today! 1.800.923-7878
Sunridge Medical
Pathology · Imaging · Biomarkers · Whole-Person Baseline

Cancer Diagnostic Testing: Build the Right Treatment Plan

A useful cancer evaluation does more than ask whether cancer is present. It identifies the exact cancer type, extent of disease, molecular features, prior treatment response and the patient’s current strength—so decisions can be more precise and unnecessary testing can be avoided.

Sunridge Medical reviews existing records and helps patients understand which pathology, imaging, laboratory, hereditary-risk or biomarker information may still be needed. Imaging and specialized testing may be coordinated with qualified outside centers and laboratories.

Review before repeatingEvidence-aware testingIntegrative treatment planning
Request a Diagnostic Review →Call 1-800-923-7878
Cancer diagnostic testing team reviewing pathology, imaging, liquid biopsy and genomic biomarker results
Pathology, imaging and molecular testing answer different questions; the strongest plan combines them in the correct order.
Cancer testing consultation

Choose Tests That Can Actually Change a Decision

Tell us where you are in diagnosis or treatment and what question remains unanswered. We can help determine which records and tests deserve physician review before adding more panels.

  • Testing begins with a defined clinical question
  • Results are connected to treatment or monitoring decisions
  • Call now for an immediate response from our Patient Care Team
Call 1-800-923-7878 →
Cancer testing consultation

Speak With Our Patient Care Team

Share your diagnosis, current treatment and the question you hope testing will answer.

* Required fields
Prefer to speak with someone now?
1-800-923-7878
  • Testing begins with a defined clinical question
  • Results are connected to treatment or monitoring decisions
  • Questions before scheduling are always welcome
Cancer Testing · Quick Answers

The Most Important Points Before Ordering More Tests

Diagnosis

A Scan Alone Usually Cannot Confirm Cancer

Imaging can show a suspicious mass and whether disease may have spread. In most cases, tissue or cells examined by a pathologist are needed to establish the diagnosis.

Pathology

The Original Report Matters

Cancer type, grade, margins, receptors and other features can change the treatment pathway. A specialist pathology review can be useful when findings are rare, complex or unexpected.

Precision oncology

Biomarkers May Change Treatment

Selected cancers should be tested for genes, proteins or genomic features that predict benefit—or lack of benefit—from targeted and immune therapies.

Efficiency

More Testing Is Not Always Better

Every test should answer a clinical question. Useful testing may prevent duplication, protect limited biopsy tissue and focus time and cost on results that can change a decision.

Start With the Foundation

No Single Test Tells the Whole Cancer Story

Cancer is diagnosed by combining the history and physical examination with imaging, laboratory data and, in most cases, a biopsy. These pieces do different jobs. A CT or MRI describes anatomy. PET can show areas of increased metabolic activity. A pathology report identifies what the cells are. Staging describes the extent of disease. Biomarker testing may identify a treatment target.

Abnormal blood tests or tumor-marker levels are not, by themselves, proof of cancer. Normal results also do not rule cancer out. Results must be interpreted in the context of the cancer type, symptoms, imaging, pathology and treatment history.

The best next test is the one that can change the next decision

Before ordering another panel, ask: What question will this answer? Is the result likely to change diagnosis, stage, treatment, safety monitoring or eligibility for a clinical trial?

Start with the broader Sunridge cancer care approach or review the cancers treated at Sunridge.
Tissue, Type and Extent

Biopsy, Pathology and Staging Create the Treatment Map

Pathology: What Is It?

A pathologist examines tissue or cells from a needle biopsy, endoscopy, surgery, bone marrow procedure or body fluid. The report may describe histologic type, grade, margins, lymph nodes, receptors, immunohistochemistry and molecular findings.

When tissue is limited, the sequence of tests matters. Confirming the diagnosis, preserving material for required biomarkers and avoiding broad low-value panels can be more useful than testing everything at once.

Staging: Where Is It?

Stage may incorporate tumor size, local invasion, lymph nodes, distant spread and disease-specific laboratory or molecular features. CT, MRI, PET/CT, ultrasound, bone imaging and endoscopic procedures are selected according to the cancer and clinical question.

A staging scan is a snapshot. Comparisons with prior studies, the same measurement method and the timing of treatment all affect interpretation.

Important: PET activity is not automatically cancer—healing, infection and inflammation can also be active. Some cancers show little PET uptake. Imaging and pathology should be interpreted together.
Precision Oncology

Biomarker Testing Can Reveal Treatment Opportunities

Biomarker testing—also called tumor profiling, genomic testing or molecular testing—looks for genes, proteins and other features of the cancer. Results may support a targeted therapy, immunotherapy, tumor-agnostic treatment or clinical trial. They can also show that a treatment is unlikely to work.

Common examples

Drivers and Receptors

Examples include EGFR, ALK, ROS1, BRAF, HER2, KRAS, NTRK, RET, estrogen and progesterone receptors. The required markers depend on cancer type and stage.

Immune treatment markers

PD-L1, MSI/MMR and TMB

PD-L1 expression, mismatch-repair deficiency, microsatellite instability and tumor mutational burden can inform immune-therapy decisions in defined settings.

Test quality

Actionable Is Not the Same as Interesting

A report may list variants of uncertain significance or theoretical matches. Evidence level, tumor type, FDA labeling, guidelines and clinical context determine whether a result is actionable.

Timing

Cancer Changes Over Time

A test from years earlier may not represent a recurrent or treatment-resistant cancer. Retesting can be appropriate when disease returns or progresses.

A companion diagnostic is a test linked to the safe and effective use of a specific medicine. A matched result increases the reason to consider a therapy; it does not guarantee response.

Learn how molecular findings connect with Stage 4 and metastatic cancer planning and cancer treatment resources.
Two Different Kinds of Genetic Information

Liquid Biopsy, Tumor Profiling and Germline Testing Are Not Interchangeable

Liquid Biopsy

A liquid biopsy looks in blood or another body fluid for tumor cells or tumor-derived DNA. It can be useful when a tissue biopsy is unsafe, tissue is insufficient or a fast treatment decision is needed.

A positive finding may guide treatment when it is validated for that use. A negative liquid biopsy does not prove the cancer lacks a biomarker; some tumors release little DNA, and tissue testing may still be needed.

Inherited-Risk Testing

Germline testing uses blood, saliva or other normal cells to look for an inherited cancer-risk variant. It may affect treatment, screening for another cancer and relatives’ care.

Tumor profiling can sometimes suggest an inherited change, but it does not replace confirmatory germline testing and appropriate genetic counseling.

Privacy and family implications matter. Before inherited-risk testing, discuss why the test is being ordered, possible results, insurance coverage and who can help interpret a positive result or a variant of uncertain significance.
Integrative Treatment Readiness

Diagnostic Planning Also Includes the Person Receiving Treatment

The cancer’s biology matters, but so do kidney and liver function, blood counts, heart and lung health, nutrition, weight change, inflammation, infection risk, medications, supplements, sleep, pain, mobility, cognition and emotional well-being. These factors can affect treatment choice, dose, tolerance and recovery.

  • Complete blood count and metabolic testing appropriate to the planned treatment
  • Nutritional risk, appetite, weight trend and muscle strength
  • Heart, lung, kidney or liver testing when treatment could affect those organs
  • Medication, supplement and infusion review for interactions
  • Symptoms, function, fall risk, fatigue, sleep and caregiver needs
  • Clear baseline measurements for later comparison

Integrative testing should be targeted and clinically interpretable. Broad specialty panels are not automatically useful simply because they measure many values. Sunridge uses the diagnostic picture to build supportive strategies around the oncology plan—not to replace established cancer diagnosis or staging.

Explore the role of coordinated supportive care in alternative and integrative cancer treatments and review safety considerations for intravenous vitamin C.
Prepare for a Useful Review

Send the Records That Show What Has Already Been Learned

Patient and family member reviewing cancer scan and pathology results with a physician during a second-opinion consultation
A complete record review can identify missing information without automatically repeating completed work.

Please provide the pathology and operative reports, imaging reports and available image files, staging documentation, tumor markers, biomarker or genomic reports, hereditary-risk testing, treatment summaries, radiation records, current laboratory results and a dated treatment timeline.

Include your current medicines, supplements and infusions; allergies; other medical conditions; recent weight or appetite change; symptoms; functional limitations; and the questions you most want answered.

  • Original pathology report and, when possible, slides or digital images
  • CT, MRI, PET and other imaging reports plus the actual studies
  • Biomarker, receptor, genomic and liquid-biopsy reports
  • Every cancer treatment with dates, response and side effects
  • Current labs and a complete medication and supplement list
Ask What Records to Send →Speak With Patient Care
Frequently Asked Questions

Cancer Diagnostic Testing Questions

Can a blood test diagnose cancer by itself?

Usually no. Blood counts, chemistry results and tumor markers can provide important clues, but most solid cancers require imaging and a biopsy for confirmation. Some blood cancers can be diagnosed using specialized blood and bone-marrow testing.

Does an abnormal tumor marker mean cancer is growing?

Not automatically. Tumor markers can rise because of noncancerous conditions, and trends are often more useful than one value. Interpret the result with imaging, symptoms, treatment timing and the cancer type.

Can PET/CT replace a biopsy?

Usually not. PET/CT can identify metabolically active areas and help stage disease or choose a biopsy site, but inflammation and infection can also be active. Tissue is often needed to confirm cancer type and biomarkers.

Should pathology ever be reviewed again?

A second review can be valuable for rare cancers, unexpected findings, uncertain margins or grades, and cases in which the exact subtype changes treatment. It may not be necessary for every diagnosis.

Who should receive broad biomarker testing?

It is commonly considered for advanced or recurrent cancers and is routine in several cancer types. The best panel and timing depend on the cancer, stage, available tissue, prior testing and treatment options.

Is liquid biopsy as accurate as tissue testing?

Liquid biopsy is useful in defined settings but can miss alterations when little tumor DNA is present. A positive validated result may guide treatment; a negative result may need follow-up tissue testing.

What is a variant of uncertain significance?

It is a genetic change whose clinical meaning is not known. A VUS should not be treated as a proven cancer driver or a proven inherited-risk mutation.

Can a biomarker match guarantee a targeted therapy will work?

No. A match increases the scientific rationale for treatment, but response also depends on the cancer type, other tumor changes, disease burden, previous treatments and the patient’s health.

Does Sunridge perform every scan and specialized test on site?

No. Sunridge reviews existing diagnostic information and may coordinate specialized imaging, pathology or laboratory testing with qualified outside facilities when needed.

Can integrative tests replace pathology, staging or standard biomarkers?

No. Integrative assessment can clarify nutrition, organ function, symptoms and treatment readiness, but it should complement—not replace—validated cancer diagnosis, staging and predictive biomarker testing.

Primary Sources & Guidelines

References

  1. National Cancer Institute. Tests and Procedures Used to Diagnose Cancer.
  2. National Cancer Institute. Surgical Pathology Reports.
  3. National Cancer Institute. Cancer Staging.
  4. National Cancer Institute. Tumor Markers.
  5. National Cancer Institute. Biomarker Testing for Cancer Treatment.
  6. National Cancer Institute. Targeted Therapy for Cancer.
  7. National Cancer Institute. Genetic Testing for Inherited Cancer Risk.
  8. National Cancer Institute. The Genetics of Cancer.
  9. National Cancer Institute. FDA-Approved Blood Tests That Can Help Guide Cancer Treatment.
  10. U.S. Food and Drug Administration. Companion Diagnostics.
  11. National Cancer Institute. Research Areas: Cancer Diagnosis.
  12. National Cancer Institute. Diagnosis and Staging Overview.

This page is educational and does not replace individual advice from a pathologist, radiologist, medical oncologist, surgeon, genetic counselor or other qualified clinician. Diagnostic and treatment outcomes cannot be guaranteed.

Ready for a Clearer Diagnostic Review?

Bring the Results You Have. We’ll Help Identify the Next Useful Question.

Whether you are newly diagnosed, comparing treatment plans, living with recurrent or Stage 4 cancer, or wondering whether older biomarker results should be revisited, our Patient Care Team can explain which records to send for a physician-directed review.

Request a Cancer Diagnostic Review →Call 1-800-923-7878

Scottsdale Clinic

14200 N Northsight Blvd #160
Scottsdale, Arizona 85260

Call Our Care Team

Toll-free: 1-800-923-7878
Local: 480-659-9135

Email

info@sunridgemedical.com

Office Hours

Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM

Visit Sunridge in Scottsdale

FREE INTRODUCTORY CALL

Speak With Our Patient Care Team

Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.

Call Now: 1-800-923-7878

This introductory call is not a medical consultation and does not establish a physician-patient relationship.

Have a Question or Share Feedback:
It's easy to get in touch with us